Numares. |Precision Diagnostics.


Locations: Houston, Texas;
Regensburg, Germany


Employees of medical and
scientific disciplines


Founded as a spin-off of
Regensburg University in Regensburg, Germany

3.5 M

Tests performed globally

Mastering Metabolite Constellations. |For Precision Diagnostics.

Numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet health care needs not addressed by single biomarker-based medicine.

Our diagnostic tests are based on the interpretation of multiple biomarkers that precisely pinpoint relevant data related to organ function. With these next-generation metabolite constellations, we develop non-invasive diagnostic tests designed to provide more precise information than the current standard tests. 

Company Milestones


Exclusive license agreement with Oxford University


FDA 510(k) submission for the AXINON®Systeman NMR platform for metabolomics-based, AI-driven diagnostics


Numares and Bruker Corporation sign agreement to enable advanced metabolomics-based clinical diagnostics


Numares begins collaborating with Mayo Clinic Laboratories to develop new diagnostic tests


Numares completes another financing round


Start of pan-European multicenter study PARASOL to evaluate metabolite constellations to detect kidney allograft rejection


Launch of AXINON® renalTX-SCORE®-U100: first metabolomics IVD test for allograft rejection diagnostics after kidney transplantation


Collaboration with Oxford University to develop a multiple sclerosis diagnostic test


1 million performed analyses


Numares completes another financing round


Launch of CE-marked IVD test AXINON® lipoFIT®-S100 for comprehensive NMR-based lipoprotein profiling


600,000 performed analyses


Successful completion of studies on kidney transplantation


Cooperation with a German laboratory network: commissioning a test system for lipoprotein profiling


200,000 performed analyses


Bulk order from a U.S. laboratory chain: installation of multiple test systems for lipoprotein profiling


Successful certification of Numares according to EN ISO 13485: 2012 as a manufacturer of in-vitro diagnostics (IVD)


100,000 performed analyses


Certification as per EN ISO 13485:2003


Measurements in large studies, such as GRAPHIC and KORA


First patent for the determination of lipoproteins in body fluids (lipoprotein profiling)


“With software-based diagnostic tests for our modular AXINON® IVD System, we are focusing on improving patient care at affordable health care costs.”

Dr. Claus Botzler, MBA

Executive Board, CTO

“AXINON® combines flexibility, personalization and high-tech - ideal conditions to make diagnostics available for everyone, to minimize healthcare costs and maximize shareholder value.”

Florian Voss

Executive Board, COO/CFO

“Although our AXINON® IVD System requires only minimal operator interaction, we provide our clients with the best support – beyond set-up and maintenance.”

Dr. Lutz Niggl

Head of Service

Supervisory Board

Volker Pfahlert, PhD

- Chairman, Supervisory Board
- Former CEO, Numares Health
- Previously with Roche and McKinsey

Kathy L. Bates, MBA

- Former Sr. Director of Partnership, Mayo Clinic
- Previously with OncoSpire Genomics and Roche

Gregory F. Heath, PhD

- Former General Manager of Diagnostics, Illumina, Inc.
- Former Sr. Vice President of Molecular Business, Roche Diagnostics

Jorg Neermann, PhD

- Board of Directors, Immunic
- Former CEO, Curexsys GmbH
- Former Partner, Life Sciences Partners

Gerhard Ries, PhD

- CEO and Co-Founder, Kineo Finance
- Former Managing Partner and Co-Founder, BioMedPartners
- Former Business Development Manager, Novartis and McKinsey

Helge Luetzen

- Sr. Investment Manager, Mayfair

You did not activate the necessary cookies for this content.

activate necessary cookies and show content